Genomic comparison of paired primary breast carcinomas and lymph node macrometastases using the Oncotype DX Breast Recurrence Score® test Journal Article
| Authors: | Boolbol, S. K.; Harshan, M.; Chadha, M.; Kirstein, L.; Cohen, J. M.; Klein, P.; Anderson, J.; Davison, D.; Jakubowski, D. M.; Baehner, F. L.; Malamud, S. |
| Article Title: | Genomic comparison of paired primary breast carcinomas and lymph node macrometastases using the Oncotype DX Breast Recurrence Score® test |
| Abstract: | Purpose: Adjuvant therapy decisions may in part be based on results of Oncotype DX Breast Recurrence Score® (RS) testing of primary tumors. When necessary, lymph node metastases may be considered as a surrogate. Here we evaluate the concordance in gene expression between primary breast cancers and synchronous lymph node metastases, based on results from quantitative RT-PCR-based RS testing between matched primary tumors and synchronous nodal metastases. Methods: This retrospective, exploratory study included patients (≥ 18 years old) treated at our center (2005–2009) who had ER+ , HER2-negative invasive breast cancer and synchronous nodal metastases with available tumor blocks from both sites. Paired tissue blocks underwent RS testing, and RS and single-gene results for ER, PR, and HER2 were explored between paired samples. Results: A wide distribution of RS results in tumors and in synchronous nodal metastases were modestly correlated between 84 paired samples analyzed (Pearson correlation 0.69 [95% CI 0.55–0.78]). Overall concordance in RS group classification between samples was 63%. ER, PR, and HER2 by RT-PCR between the primary tumor and lymph node were also modestly correlated (Pearson correlation [95% CI] 0.64 [0.50–0.75], 0.64 [0.49–0.75], and 0.51 [0.33–0.65], respectively). Categorical concordance (positive or negative) was 100% for ER, 77% for PR, and 100% for HER2. Conclusions: There is modest correlation in continuous gene expression, as measured by the RS and single-gene results for ER, PR, and HER2 between paired primary tumors and synchronous nodal metastases. RS testing for ER+ breast cancer should continue to be based on analysis of primary tumors. © 2019, Springer Science+Business Media, LLC, part of Springer Nature. |
| Keywords: | breast cancer; lymph node; genomics; metastases; oncotype dx®; recurrence score® |
| Journal Title: | Breast Cancer Research and Treatment |
| Volume: | 177 |
| Issue: | 3 |
| ISSN: | 0167-6806 |
| Publisher: | Springer |
| Date Published: | 2019-10-01 |
| Start Page: | 611 |
| End Page: | 618 |
| Language: | English |
| DOI: | 10.1007/s10549-019-05346-1 |
| PUBMED: | 31302854 |
| PROVIDER: | scopus |
| PMCID: | PMC7472831 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 November 2019 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work